Literature DB >> 3011017

Oxidation of 1,4-dihydropyridines by prostaglandin synthase and the peroxidic function of cytochrome P-450. Demonstration of a free radical intermediate.

C Bäärnhielm, G Hansson.   

Abstract

Oxidation of 1,4-dihydropyridines by the hydroperoxidic function of cytochrome P-450 and prostaglandin synthase was investigated using felodipine as a model substance. Nifedipine and the 2,6-dichlorophenyl analogue of felodipine were used in some experiments with similar results. Felodipine was metabolized to a pyridine metabolite in vitro when incubated with liver microsomes and cumene hydroperoxide, as well as with ram seminal vesicle microsomes and arachidonic acid. The oxidation of 1,4-dihydropyridines is proposed to proceed via formation of a free radical intermediate, judging from EPR analysis with the spin trap POBN. When reduced glutathione was added the EPR signal was decreased as well as the formation of the pyridine metabolite while an oxidation of glutathione was observed. This effect was due to a reduction of the radical intermediate back to felodipine by glutathione. Felodipine interacts with the hydroperoxidase activity of prostaglandin synthase, since the pyridine metabolite was formed also when 15-hydroperoxyeicosatetraenoic acid was used as a substitute for arachidonic acid. Indomethacin could only inhibit the metabolism of felodipine when arachidonic acid was used as substrate. The cooxidation of felodipine by prostaglandin synthase is associated with an increased metabolism of arachidonic acid. This was further supported by a stimulated oxygen consumption and an increased formation of prostaglandin E2.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3011017     DOI: 10.1016/0006-2952(86)90105-x

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  7 in total

1.  Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics of felodipine--and its potential clinical relevance.

Authors:  B Edgar; D Bailey; R Bergstrand; G Johnsson; C G Regårdh
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Factors affecting the pharmacokinetics of nifedipine.

Authors:  A G Renwick; J Le Vie; V F Challenor; D G Waller; B Gruchy; C F George
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

3.  The trans-hepatic extraction of nifedipine.

Authors:  V F Challenor; D G Waller; A G Renwick; B S Gruchy; C F George
Journal:  Br J Clin Pharmacol       Date:  1987-10       Impact factor: 4.335

Review 4.  Felodipine clinical pharmacokinetics.

Authors:  P H Dunselman; B Edgar
Journal:  Clin Pharmacokinet       Date:  1991-12       Impact factor: 6.447

5.  Attenuation of renal ischaemic injury by felodipine.

Authors:  P G Thalén; M I Nordlander; M E Sohtell; L E Svensson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-04       Impact factor: 3.000

6.  Nisoldipine: kinetics and effects on blood pressure and heart rate in patients with liver cirrhosis after intravenous and oral administration.

Authors:  J van Harten; P van Brummelen; J H Wilson; M T Lodewijks; D D Breimer
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

7.  The pharmacokinetics of oral nifedipine--a population study.

Authors:  A G Renwick; D R Robertson; B Macklin; V Challenor; D G Waller; C F George
Journal:  Br J Clin Pharmacol       Date:  1988-06       Impact factor: 4.335

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.